Virtual Library

Start Your Search

Y. Li



Author of

  • +

    P1.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 224)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
    • Presentations: 1
    • +

      P1.08-036 - Long-Term Survival after Surgical Treatment for Thymic Carcinoma (ID 262)

      09:30 - 17:00  |  Author(s): Y. Li

      • Abstract
      • Slides

      Background:
      Thymic carcinoma is a type of highly malignant tumor that originates from the thymic epithelium. It is rare and distinct from thymoma. Treatment methods and prognosis of thymic carcinoma remain controversial. To date, three studies with relatively large sample populations have been conducted based respectively on the Surveillance, Epidem iology and End Results database in the United States, the European Society of Thoracic Surgeons, and the Japanese multicenter database. This paper retrospectively analyzes survival data from a large-sample multicenter database in China.

      Methods:
      The Chinese Alliance for Research of Thymoma (ChART), established in June 2012 in China, constructed a retrospective database of patients with thymic epithelial tumors. This database enrolled 1,930 patients, including 369 with thymic carcinoma. In this study, we analyzed clinical, pathologic and treatment imformation, measured long-term survival rates, and identified relevant prognostic factors.

      Results:
      Among 369 thymic carcinoma underwented radical intended surgery, 211 underwent R0 resection; 34, R1 resection; and 84, R2 resection. The 3-, 5-, and 10-year survival rates were 78.3%, 67.1%, and 47.9%, respectively. The survival rates of the patients at different Masaoka-Koga stages were significantly different (P < 0.001). The survival rate of the patients who underwent complete resection (R0) was significantly higher than that with incomplete resection (R1/R2)(P < 0.001). Postoperative chemotherapy did not significantly affect patient survival (P = 0.873). Postoperative radiotherapy significantly improved the overall survival not only of the patients with R1/R2 resection but also of those with stage III/IV disease who underwent R0 resection. Multivariate analyses showed that R0 resection, Masaoka-Koga stage and postoperative radiotherapy were major prognostic factors of overall and disease-free survival. Figure 1



      Conclusion:
      Surgery remains the primary treatment for thymic carcinoma. R0 resection was the main factor of prognosis. For patients with stage III/IV disease who had undergone R0 resection and all the patients who had undergone R1+R2 resection, postoperative radiotherapy should be administered.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.